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Inhibition of poly-LacNAc 
biosynthesis with release of 
CMP-Neu5Ac feedback inhibition 
increases the sialylation of 
recombinant EPO produced in  
CHO cells
Chung-Geun Lee1, Myung Jin Oh2,3, Seung-Yeol Park4, Hyun Joo An2,3 & Jung Hoe Kim1
Sialylation of recombinant therapeutic glycoproteins modulates their pharmacokinetic properties 
by affecting their in vivo half-life. N-glycan branching on glycoproteins increases the number of 
potential attachment sites for sialic acid. Here, we introduce a new approach for increasing the 
sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells by modulating poly-
N-acetyllactosamine (poly-LacNAc) biosynthesis. We did not observe an increase in rhEPO sialylation, 
however, until the feedback inhibition by intracellular cytidine monophosphate-N-acetylneuraminic 
acid (CMP-Neu5Ac), which is a limiting factor for sialylation, was released. Thus, we found that a 
combined approach inhibiting poly-LacNAc biosynthesis and releasing CMP-Neu5Ac feedback inhibition 
produces the most significant increase in rhEPO sialylation in metabolically engineered CHO cells. 
Furthermore, a detailed analysis of the resulting N-glycan structures using LC/MS revealed increased 
tri- and tetra- sialylated N-glycan structures accompanied by a reduction of di-sialylated N-glycan 
structures. These results validate our new approach for glycosylation engineering, and we expect this 
approach will be useful in future efforts to enhance the efficacy of other therapeutic glycoproteins.
Glycosylation contributes to several properties of therapeutic drugs, such as pharmacokinetics, and immuno-
genicity1,2. Proper modulation of glycosylation is a major issue in producing recombinant therapeutic glycopro-
teins3,4. Sialylation of a glycoprotein’s N-glycans modulates the life span over which that specific protein molecule 
circulates in vivo. This occurs because sialylation prevents the recognition of galactosyl residues by hepatocyte 
asialoglycoprotein receptors (ASGPRs), which triggers protein degradation5,6. Thus, various methods have been 
developed for increasing sialylation7–13.
N-acetylglucosamine (GlcNAc) is the initial glycan residue in N-glycan branches. Initial N-glycan branches 
are extended by the sequential attachment of galactosyl- and sialyl- residues. The degree of N-glycan branch-
ing determines the number of available sites for the attachment of terminal sialic acid residues. Early studies 
found that antennary structures are related to the intracellular level of UDP-GlcNAc14. GlcNAc supplementa-
tion during cell culture increases N-glycan branching15. Subsequently, the storage of UDP-GlcNAc was found 
to be limited such that excess UDP-GlcNAc is shunted toward other glycosylation pathways as well16. Another 
attempt at enhancing N-glycan branching involved the overexpression of α-1,3-mannosyl-glycoprotein 
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2-β-N-acetylglucosaminyltransferase (MGAT), which is required to form the GlcNAc branching on the N-glycan 
core structure (Man3GlcNAc2). Notably, while overexpression of MGAT-4 and MGAT-5 does induce N-glycan 
branching, it also increases poly-LacNAc chain formation17,18.
Poly-LacNAc consists of repeated N-acetyllactosamine (Galβ1-4GlcNAc)n residues formed as GlcNAc res-
idues are attached to galactosyl termini via the enzymatic activity of β-1,3 N-acetylglucosaminyltransferase 
(β3gnt) (Fig. 1). Of the several homologs of β3gnt, β3gnt2 is crucial enzyme for synthesis of poly-LacNAc in CHO 
cells19. rhEPO containing poly-LacNAc is cleared from the blood faster than the EPO lacking poly-LacNAc5. Thus, 
reducing poly-LacNAc chains on therapeutic recombinant glycoproteins improves their half-life and efficacy in 
vivo. The biosynthetic pathways that form N-glycan branches and poly-LacNAc chains both utilize GlcNAc and 
galactose as building blocks. Thus, we hypothesized that rhEPO sialylation may increase when poly-LacNAc 
synthesis is inhibited because this would increase the availability of GlcNAc and galactosyl residues for N-glycan 
branch synthesis.
In this study, we introduce a new approach for increasing rhEPO sialylation by modulating N-glycan branch 
synthesis. We found that β3gnt2-depleted CHO cells produce rhEPO without poly-LacNAc, but with increased 
tri- and tetra-antennary N-glycans. Notably, however, sialylation of rhEPO from β3gnt2-depleted CHO cells 
were still not increased due to feedback regulation by intracellular CMP-Neu5Ac20,21. We were able to overcome 
this issue by depleting β3gnt2 in EC2-1H9-CTSTrEKm cells, which are insensitive to this feedback inhibition. 
In summary, by modifying CHO cells to increase N-glycan branching synthesis and reduce feedback inhibition 
by CMP-Neu5Ac, we were able to produce rhEPO with significantly more N-glycan branching and sialylation.
Results
Knock-down of β3gnt2 reduces polylactosaminylation of rhEPO. We first attempted to reduce 
poly-LacNAc by inhibiting the expression of β3gnt2 using siRNA. We expected this would increase N-glycan 
branching and terminal sialylation. To this end, we treated the rhEPO-producing CHO cell line EC2-1H9 with 
siRNAs designed by Invitrogen to specifically target the β3gnt2 sequence listed in GenBank (NCBI). Three days 
after siRNA transfection, we harvested the cells and analyzed the expression of β3gnt2 by western blot. As shown 
in Fig. 2A and B, siRNA-mediated knockdown effectively reduces β3gnt2 expression in the transfected cells. We 
next validated the effect of β3gnt2 knock-down with poly-LacNAc-specific lectin. After pulling down rhEPO from 
cell supernatants using an anti-EPO antibody, we performed a western blot using Lycopersicon esculentum lectin 
(LEL) and the same anti-EPO antibody. Consistent with the expression pattern of β3gnt2, rhEPO from β3gnt2-de-
pleted CHO cells showed a reduced level of poly-LacNAc when compared to control cells (Fig. 2C and D).
Inhibition of polyLacNAc biosynthesis enhances N-glycan branching. Through western blot 
experiments, we found that knock-down of β3gnt2 decreases the polylactosaminylation of rhEPO. In order to 
confirm our observation, released N-glycans on rhEPO were analyzed using a chip-based nano-LC/qTOF-MS 
system. Representative extracted compound chromatograms (ECCs) of N-glycans identified in rhEPO were 
shown in Fig. S1. Initially, N-glycan compositions were assigned according their accurate masses and known 
EPO glycosylation22. Modifications such as O-acetylation (OAc) and dehydration (-H2O) often found in EPOs 
was also considered23–25. Total thirty two N-glycan compositions corresponding to 62 isomer-specific mole-
cules were separated on a PGC column. In general, smaller and neutral glycans eluted earlier, while larger and 
acidic glycans eluted later. Glycan structures were further identified by the combination of MS/MS analysis and 
glyco-synthetic pathway. The intensity of each peak was normalized across total glycan intensities to determine 
Figure 1. Schematic structure of a typical poly-LacNAc type N-glycan. Poly-N-acetyllactosamine (Poly-
LacNAc) comprises repeated Galβ1-4GlcNAc disaccharides, called N-acetyllactosamine (LacNAc). The 
biosynthesis of poly-LacNAc is accomplished by the enzymatic action of β-1,3 N-acetylglucosaminyltransferase 
(β3gnt) which catalyzes the addition of GlcNAc to N-glycan Gal termini. ALG, asparagine linked glycosylation 
gene, FUT, fucosyltransferase, MGAT, mannosyl-glycoprotein N-acetylglucosaminyltransferase, β4GALT, 
beta-1,4 galactosyltransferase, ST3GAL, beta-1,4-galactoside alpha-2,3 sialyltranferase, β3GNT, beta-1,3 
N-acetylglucosaminyltransferase.
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the distribution of N-glycan branching (Fig. 3A and C) and the degree of sialylation (Fig. 3B and D), respec-
tively. The classification of glycan branching could be basically determined by the number of N-acetylhexosamine 
(HexNAc) in N-glycan composition considering N-glycan biosynthesis process. For example, we categorized 
N-glycans having four HexNAc into bi-antennary group because two HexNcA attached to asparagine on a 
protein, and leaving two HexNAc attached on N-glycan core as two antennae. Although polylactosaminylated 
bi- or tri-antennary N-glycans are biologically possible, most polylactosaminylation on recombinant EPOs was 
found in tetra-antennary N-glycans24,26,27. Indeed, polylactosaminylation was observed to have primarily on 
tetra-antennary rather than bi- or tri-antennary N-glycans by our previous study22. Consistent with our lectin 
blot results, we found a drastic reduction in the ratio of polyLacNAc from 15.68% to 1.99%. Moreover, rhEPO 
produced in siRNA-treated CHO cells showed increased tri-antennary and tetra-antennary N-glycans when 
compared with rhEPO produced in control CHO cells (32.68% vs. 23.13% for tri-antennary N-glycans; 31.44% 
vs. 19.54% for tetra-antennary N-glycans). Bi-antennary N-glycans, in contrast, were reduced from 41.67% to 
34.12%. In terms of sialylation itself, however, we did not observe any significant difference in the distribution 
of sialylated N-glycans (Fig. 3B and D) or in the amount of total sialic acid content (Fig. 3E) despite the increase 
in antennal branching. We supposed this unaltered sialylation was due to shortage of intracellular CMP-Neu5Ac 
pool in the cells. To identify this hypothesis, we measured intracellular CMP-Neu5Ac as described in methods 
section. We found that the intracellular CMP-Neu5Ac levels in β3gnt2-specific siRNA-treated EC2-1H9 cells 
were similar to control (Fig. S2A). Next, we measured the expression level of st3gal4, which encodes a major 
α2,3-sialyltransferase28,29, in both control CHO cells and siRNA-treated EC2-1H9 CHO cells. We found no sig-
nificant change in the level of st3gal4 caused by β3gnt2 depletion (Fig. S2B). Furthermore, in our detailed analysis, 
we found that the increased tri- and tetra-antennary N-glycans tend to have terminal galactose residues uncapped 
by sialic acid residues (Table S1). This suggests intracellular CMP-Neu5Ac may be the limiting factor reducing 
N-glycan branching and sialylation rather than galactose.
Increased N-glycan branching further enhances sialylation of rhEPO. Under the assumption that 
insufficient intracellular pools of CMP-Neu5Ac are limiting N-glycan branching and sialylation in the context 
of reduced polyLacNAc synthesis, we attempted to regulate polylactosaminylation in EC2-1H9-CTSTrekm 
cells. EC2-1H9-CTSTrekm are CHO cells engineered to show increased sialylation via the over-expression 
of sialuria-like mutated rat UDP-N-acetyl-glucosamine-2-epimerase (GNE), CMP-Neu5Ac transporter 
(CMP-SAT), and human α2,3-sialyltransferase (ST)30. As in previous experiments, we transfected EC2-
1H9-CTSTrekm cells with β3gnt2-specific siRNAs. After confirming their over-expression of GNE by RT-PCR 
Figure 2. Decreased poly-LacNAc via β3gnt2 knock-down. (A) Depletion of β3gnt2 by siRNA was determined 
by western blot. Lane 1, EC2-1H9 cells. Lane 2, EC2-1H9 cells treated with siRNA against β3gnt2. (B) 
Quantification of panel A using Image J. The band intensities of β3gnt2 were normalized by the intensities of 
β-actin. (C) Lectin blot results show reduced polylactosaminylation of rhEPO purified from β3gnt2-depleted 
CHO cells. For detection of polylactosaminylation, 1 μg of purified rhEPO was used. (D) Quantification of the 
data in C. LEL lectin band intensities were normalized by EPO band intensities. The data shown are presented as 
means ± S.E.M. from three independent experiments each with duplicate samples. **P < 0.01 (Student’s t-test).
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(Fig. 4A), we measured intracellular CMP-Neu5Ac of EC2-1H9, EC2-1H9-CTSTrekm and β3gnt2-depleted EC2-
1H9-CTSTrekm. We found the increased expression of GNE in EC2-1H9-CTSTrekm led to a 7-fold increase 
of intracellular CMP-Neu5Ac when compared to EC2-1H9 control cells (Fig. 4B). We also confirmed the 
siRNA-mediated depletion of β3gnt2 by western blot (Fig. 4C and D). Before determining whether this increased 
intracellular sialic acid led to further sialylation of the expanded N-glycan branches, we first performed a western 
blot experiment using LEL and confirmed a reduced level of polyLacNAc induced by β3gnt2 knock-down (Fig. 4E 
and F).
We next performed an LC/MS experiment to identify qualitative and quantitative changes of N-glycan 
antennary structures and the degree of terminal sialylation following reduced poly-LacNAc by β3gnt2 inhi-
bition. As shown in Fig. 5A to D, we found altered sialylation patterns associated with changes in N-glycan 
antennary distributions. In particular, tri-sialylated N-glycans were significantly increased to 28.30% in rhEPO 
produced from EC2-1H9-CTSTrekm cells treated with β3gnt2-specific siRNAs compared with rhEPO from con-
trol EC2-1H9-CTSTrekm cells (18.36%). The level of tetra-sialylated N-glycans was also elevated from 2.93% 
in control cells to 8.05% in β3gnt2-depleted EC2-1H9-CTSTrekm cells, despite the total ratio remaining less 
than 10%. Finally, we measured rhEPO sialylation via derivatization of sialic acids with OPD as described in the 
Methods section (Fig. 5E). Human erythropoietin has a maximum sialic acid content of 14 moles because it has 
3 N-glycan sites capable of accepting 4 sialic acid residues each and 1 O-glycan site capable of accepting 2 sialic 
acid residues. While EC2-1H9-CTSTrekm and EC2-1H9 cells produce rhEPO with 7.6 moles and 6.2 moles of 
sialic acid, respectively, we found an average of 8.8 moles of sialic acid associated with the rhEPO produced by 
β3gnt2-depleted EC2-1H9-CTSTrekm cells.
Discussion
Many attempts have been made to promote the sialylation of therapeutic proteins in an effort to enhance their sta-
bility in vivo. These include attempts at N-acetylmannosamine (ManNAc) supplementation8 and CMP-Neu5Ac 
transporter overexpression9,10. Recently, we reported enhanced sialylation of rhEPO by modulation of intracellu-
lar CMP-Neu5Ac, which is a key limiting factor for sialylation11.
Here, we further improve rhEPO sialylation by not only modulating intracellular CMP-Neu5Ac, but by addi-
tionally enhancing N-glycan branch formation. In previous studies, recombinant interferon (IFN)-γ and rhEPO 
with more antennary structures were obtained via the overexpression of MGAT-4 and −5, which are responsible 
for the formation of tri- and tetra-antennary structures17,18. These studies, however, found that this increased 
N-glycan branch formation was accompanied by increases in poly-LacNAc, which itself reduces protein stability 
in vivo. We noted several advantages of restraining the polylactosaminylation of glycoproteins. First, the inhibi-
tion of poly-LacNAc biosynthesis can increase N-glycan branch formation by shunting GlcNAc and galactose 
Figure 3. Comparison of N-glycan profiles and sialic acid contents. Distributions of N-glycan antennal 
branching (A) and sialylation (B) presented using Extracted Compound Chromatograms (ECCs) with the 
control above and the β3gnt2-depleted cells below. The data in (A) and (B) are quantified in (C) and (D), 
respectively. (E) Sialic acid content was determined using the OPD-labeling method. The data shown are 
presented as means ±S.E.M. from three independent experiments each with duplicate samples. NS, not 
significant (Student’s t-test).
www.nature.com/scientificreports/
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from linear elongation (poly-LacNAc) to horizontal extension (branching)14–16. Second, the in vivo half-life of 
rhEPO with poly-LacNAc was much shorter than rhEPO without poly-LacNAc5. Consistent with previous stud-
ies14–16, we found that inhibition of poly-LacNAc synthesis induces the formation of N-glycans with more anten-
nary structures. We were therefore surprised to find that rhEPO produced in β3gnt2-depleted CHO cells did not 
show significantly more sialylation than that produced in control cells.
Intracellular CMP-Neu5Ac was found to limit sialylation20,21. We therefore suspected feedback inhibition 
induced by the accumulation of intracellular CMP-Neu5Ac was limiting the sialylation of rhEPO produced by 
β3gnt2-depleted CHO cells. Previously, we were able to overcome this issue via the overexpression of a mutated 
rat GNE30. We therefore sought to further increase rhEPO sialylation using EC2-1H9-CTSTrEKm CHO cells, 
which overexpress key sialylation enzymes. By knocking down β3gnt2 in these EC2-1H9-CTSTrEKm cells, we 
were able to obtain rhEPO with both increased sialylation and improved N-glycan branching. A detailed analysis 
of N-glycosylation for this rhEPO using LC/MS revealed increases in tri- and tetra-sialylated N-glycans of more 
than 1.5- and 2.7-fold, respectively. We found, though, that these tri- and tetra- antennary structures were not 
fully occupied by sialic acid residues. It is possible that secreted sialidases are hydrolyzing the terminal sialyl res-
idues of rhEPO31–33. This hypothesis should be addressed in future studies.
In summary, we present here a comprehensive approach for enhancing the sialylation of rhEPO produced 
from CHO cells by modulating poly-LacNAc synthesis. Inhibiting poly-LacNAc synthesis prevents the inefficient 
use of GlcNAc and galactose residues, shunting them into the formation of more antennary structures, which 
allow for enhanced sialylation. The further release of feedback inhibition by intracellular CMP-Neu5Ac promotes 
sialylation of the increased antennary structures. This new approach represents a significant contribution to the 
optimized therapeutic efficacy of not only rhEPO, but also other recombinant therapeutic glycoproteins.
Materials and Methods
Cell lines and culture maintenance. EC2-1H9, a CHO cell line producing recombinant human EPO, was 
provided by Dr. Hyo Jeong Hong (Antibody Engineering Research Unit, Korea Research Institute of Bioscience 
and Biotechnology, Yuseong-gu, Daejeon, Korea). EC2-1H9-CTSTrekm is a sialylation pathway enhanced cell 
line previously constructed in our group based on EC2-1H9. This cell line was constructed by overexpressing 
mutated rat UDP-N-acetyl-glucosamine-2-epimerase (GNE), CMP-Neu5Ac transporter (CMP-SAT) and human 
α2,3-sialyltransferase (ST). Cell lines were cultured with MEM-α (Gibco) supplemented with 10% (v/v) FBS 
Figure 4. Poly-LacNAc is reduced in CHO cells with high intracellular CMP-Neu5Ac. (A) The over-expression 
of GNE in EC2-1H9-CTSTrekm9 confirmed by RT-PCR. Lane 1, EC2-1H9 cells; Lane 2, EC2-1H9-CTSTrekm 
cells; Lane 3, EC2-1H9-CTSTrekm cells treated with β3gnt2-specific siRNAs. (B) Bypassing CMP-Neu5Ac 
feedback inhibition via GNE over-expression increases intracellular CMP-Neu5Ac. (C) Expression of β3gnt2 
was examined in EC2-1H9-CTSTrekm cells with depletion of β3gnt2 using siRNA. Lane 1, EC2-1H9 cells.  
Lane 2, EC2-1H9-CTSTrekm cells. Lane 3, EC2-1H9-CTSTrekm cells treated with siRNA against β3gnt2.  
(D) Quantification of panel C was shown. The band intensities of β3gnt2 were normalized by the intensities 
of β-actin. (E) Polylactosaminylation of purified rhEPO measured by western blot using LEL. For detection 
of polylactosaminylation, 1 μg of purified rhEPO was used. (F) Quantification of the data in C. The LEL lectin 
band intensity was normalized by the EPO band intensity. The data shown are presented as means ± S.E.M. 
from three independent experiments each with duplicate samples. **P < 0.01, *P < 0.05 (Student’s t-test).
www.nature.com/scientificreports/
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(Gibco), 3.5 g/L glucose, 20 nM MTX (methotrexate; Sigma), and 1% (v/v) Ab-Am (antibiotic-antimycotic solu-
tion; Gibco) in a humidified atmosphere containing 5% CO2 at 37 °C. For the EC2-1H9-CTSTrekm cells, 400 μg/
mL hygromycin B (Invitrogen) and 500 μg/mL Zeocin (Invitrogen) were added for the selection of the transfected 
genes.
Inhibition of β3gnt2 expression by siRNA transfection. The siRNA sequence targeting 
Chinese hamster β3gnt2 mRNA (GenBank accession no. XM_003502146.3) was obtained and annealed 
by Invitrogen (Carlsbad, CA); sense strand: 5′-GAAGAAATGCGCAAAGAA-3′, anti-sense strand: 
5′TTCTTTGCGCATTTCTTC-3′. The siRNA was transfected into CHO cells using Lipofectamine™ RNAiMAX 
reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Twenty-four hours after siRNA 
transfection, the culture media was replaced with serum-free media (CHO-S-SFM II; Gibco) to enrich for rhEPO 
and exclude serum proteins. Three days after this media change, the cells were harvested to analyze the effects of 
siRNA-mediated mRNA suppression.
Determination of expression level of genes by RT-PCR and qRT-PCR. Total RNA was extracted 
from transfected CHO cells using RNeasy Mini Kit from Qiagen. One μg of this total RNA isolated from each cell 
type was used as a template for cDNA production via RT-PCR using the AccuPower RT-PCR PreMix (Bioneer) 
according to the manufacturer’s instructions. GNE/MNK transcript levels were determined by RT-PCR using 
following primer pair: forward, 5′- GGT GAC CAC CGA CAT TAA GCA TTC C-3′; reverse, 5′- GGA CAG 
GAG AAC TTT GTG ACG CTC-3. β-actin was simultaneously amplified as an internal control using 5′-ATG 
GAT GAC GAT ATC GCT GCG CTC G-3′ and 5′-CCA TCG TCC ACC GCA AAT GCT TCT AG-3′ for the 
forward and reverse primers, respectively. The amplified PCR products were separated on a 0.8% agarose gel and 
visualized by ethidium bromide (EtBr) staining. The band intensity of GNE/MNK was normalized by intensity 
of β-actin.
The expression of endogenous st3gal4 was measured by qRT-PCR using a CFX96 touch real-Time PCR detec-
tion system (Bio-Rad, Hercules, CA) and iQTM SYBR Green Supermix (Bio-Rad, Hercules, CA) according to the 
manufacturer’s instructions. β-actin was simultaneously amplified as an internal control. The primers used were: 
st3gal4 forward, 5′-AGT GTC GTC GTT GTG TTG TG-3′; reverse, 5′-AGA AAA CAA CCC AGA CAC GC-3′; 
β-actin forward, 5′-AGC TGA GAG GGA AAT TGT GCG-3′; reverse 5′-AAT GAG CGG TTC CGT TGC-3′.
Figure 5. Enhanced N-glycan branch formation leads to a further increase in rhEPO sialylation. N-glycan 
antennary distribution (A) and sialylation (B) presented using Extracted Compound Chromatograms (ECCs) 
with EC2-1H9 control above, EC2-1H9-CTSTrekm in the middle, and β3gnt2-depleted EC2-1H9-CTSTrekm 
below. The data in (A) and (B) are quantified in (C) and (D), respectively. (E) Sialic acid content was determined 
using the OPD-labeling method. The data shown are presented as means ±S.E.M. from three independent 
experiments each with duplicate samples. **P < 0.01 (Student’s t-test).
www.nature.com/scientificreports/
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Western blotting. β3gnt2 expression was measured by western blotting. Cells were lysed using RIPA buffer 
(Thermo Scientific; Rockford, IL) according to the manufacturer’s instructions. After harvesting total pro-
tein extracts from each cell sample, their concentration was measured using the Quant-iT™ protein assay kit 
(Invitrogen). A 10 μg sample of each total cell lysate was subjected to SDS-PAGE and transferred to a PVDF mem-
brane (Millipore Corp., Bedford, MA). These membranes were blocked with 5% BSA in TBS-T (140 mM NaCl, 
10 mM Tris-HCl, and 0.05% Tween 20, pH 8.0) for an hour at room temperature followed by a 4 °C overnight 
incubation with biotinylated antibodies for β3gnt2 and β-actin. Then, the membranes were washed three times 
for 5 min with TBS-T and incubated at room temperature for 1 hour with an HRP-conjugated mouse-anti-goat 
IgG antibody for β3gnt2 and a goat-anti-mouse IgG antibody (Santa Cruz) to detect the β-actin antibody. For 
detection of polylactosaminylation, 1 μg of purified rhEPO and biotinylated antibodies (Lycopersicon Esculentum 
Lectin; LEL, anti-EPO antibody) were used. After incubation with the antibodies, ExtrAvidin-peroxidase (Sigma) 
for LEL and HRP-conjugated goat-anti-mouse IgG antibody (Santa Cruz) for the anti-EPO antibody were used as 
secondary antibodies. The blots were then developed using an ECL kit (Thermo Scientific; Rockford, IL). Signal 
quantification was performed using the ImageJ software from the NIH. β3gnt2 and LEL band intensities were 
normalized by the signal from the β-actin antibody and anti-EPO antibody, respectively.
Purification of rhEPO and determination of its sialic acid contents. Three days after replacing the 
media with serum-free media, the collected culture media was filtered using 0.45 μm filters (Sartorius, Göttingen, 
Germany) and dialyzed against PBS (pH 7.4) at 4 °C. To purify rhEPO, the dialyzed media was combined with 
EPO Purification Gel (MAIIA Diagnostics, Uppsala, Sweden), washed, and eluted according to the manufactur-
er’s directions. Purified rhEPO was then dialyzed against distilled water at 4 °C and stored at −80 °C until use. The 
concentration was measured using the Quant-iT™ protein assay kit (Invitrogen).
The sialic acid content of the purified rhEPO was measured as previously described34. Sialic acid was 
released from purified rhEPO under mildly acidic conditions. This free sialic acid was then mixed with OPD 
(o-phenylenediamine-2HCl; Sigma) and incubated at 80 °C for 40 min. The amount of OPD-labeled sialic acid 
was analyzed using a C18 reversed-phase column (Shim-pack CLC-ODS; Shimadzu, Kyoto, Japan) with a fluo-
rescence detector (excitation at 230 nm and emission at 420 nm, Waters).
N-glycan release and enrichment. N-glycans were released and enriched according to previously opti-
mized procedures22. Briefly, purified rhEPO was denatured by rapid thermal cycling (25~100 °C) in a solution 
containing 100 mM ammonium bicarbonate and 5 mM dithiothreitol. After cooling, the samples were incubated 
with PNGase F (Promega) at 37 °C for 16 hours. Graphitized carbon cartridges were washed with 80% acetoni-
trile/ 0.10% trifluoroacetic acid (v/v) in water, followed by conditioning with pure water. The released N-glycan 
solutions were loaded onto the cartridges and washed with water to remove salts and buffer materials. N-glycans 
were then eluted by the addition of 40% acetonitrile and 0.05% trifluoroacetic acid (v/v) in water. Finally, the 
samples were dried under vacuum.
Profiling the N-glycosylation of rhEPO by LC/MS. Purified N-glycan fractions were separated and 
analyzed using a nano-LC/Q-TOF MS system. For each sample, 2.0 μL (corresponding to 3 μg of EPO) were 
injected by an autosampler onto a porous graphitized carbon nano-LC chip (Agilent). A glycan elution gradient 
was applied to the analytical column at 0.3 μL/min using solutions of (A) 3.0% acetonitrile and 0.5% formic acid 
(v/v) in water, and (B) 90.0% acetonitrile and 0.5% formic acid in water. N-glycans were eluted with 6% B, 0.00–
2.50 min; 6–16% B, 2.50–5.00 min; 16–44% B, 5.00–15.00 min; and 44–100% B, 40.00–50.00 min. The stationary 
phase was washed out with 100% B for 10 min before returning to 6% B. MS spectra were acquired in positive ion 
detection over a mass range of m/z 600–2000 with an acquisition time of 1.5 seconds per spectrum. After data 
acquisition, the raw LC/MS data were processed using the Molecular Feature Extractor algorithm included in the 
MassHunter Qualitative Analysis software (version B.07.00 SP2, Agilent Technologies). MS peaks were filtered 
with a signal-to-noise ratio of 5.0 and parsed into individual ion species. Taking into account charge state infor-
mation, expected isotopic distribution, and retention times, the molecular feature extractor algorithm generated 
a list of all compound peaks in the sample. Using this information, a list of all compound peaks in the sample was 
generated, with abundances represented by chromatographic peak areas.
N-glycan identification by accurate mass. We used in-house computer algorithms to determine 
N-glycan compositions from LC/MS data by accurate mass35,36. Deconvoluted masses were compared against 
theoretical glycan masses using m/z error tolerance of 5 ppm. According to known glycosylation patterns of 
recombinant EPOs23–25, N glycan compositions consisting of hexose (Hex), N-acetylhexosamine (HexNAc), 
fucose (Fuc), N-acetylneuraminic acid (NeuAc), O-acetylation (OAc) and dehydration (-H2O) were only consid-
ered. High mannose N-glycans or N-glycolylneuraminic acid (NeuGc) were not considered because no associated 
fragments were examined from LC/MS/MS data.
Examining the levels of intracellular CMP-Neu5Ac in CHO cells. The intracellular CMP-Neu5Ac 
concentration of CHO cells was determined as previously described37. Briefly, cells were lysed in ice-cold 75% 
(v/v) ethanol using a sonicator and their supernatants were obtained after centrifugation at 13,000 rpm at 4 °C 
for 10 min. CMP-Neu5Ac was lyophilized and dissolved in 120 μl of 40 mM phosphate buffer (pH 9.2), followed 
by centrifugation. Filtrates were obtained using a centricon (MWCO, 10,000) and then added to a CarboPac 
PA-1 column (Dionex, Sunnyvale, CA). The amount of CMP- Neu5Ac was analyzed using an Abs260 absorbance 
detector (model 486; Waters). The intracellular CMP-Neu5Ac concentration was normalized to the number of 
cells used in the analysis.
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